Excited to be part of this paper on immune system changes across the lifespan, from babies to old age, led by my friend & colleague Duygu Uçar at the Jackson Laboratory. I've attached an infographic explaining the key points relevant to immune aging. https://t.co/zndBCw4ME7
🧪 [68Ga]Ga-DOTATATE PET in metastatic epNEC (prospective study)
📈 High, uniform SSTR expression on DOTATATE PET: only 13%
⚠️ Most patients showed absent or heterogeneous uptake
🛑 Routine SSTR PET may have limited value in unselected epNECs
🔗 https://t.co/tY8wdImp9J
@OncoAlert
🫁 Actualización clasificación de TNE pulmonares (IASLC)
🔹 Incorpora Ki-67 como criterio diagnóstico
🔹 Reconoce NET G3 pulmonar
🔹 Transición de “carcinoide” hacia “NET”
🔹 Integra de nuevos conocimientos moleculares
🎯 Más precisión diagnóstica y mejor estratificación
🔗 https://t.co/2iXcDEBW93
ZG006- Phase II trial with trispecific T Cell Engager DLL3/DLL3/CD3 in NEC at @ASCO#ASCO26
ORR if DLL3 high at 30 mg 56%, DOR 11.7 months
🙌🏻Consistent - DLL3 works in NEC
Muchas graciasss
Ahora urge pasar a la acción (pero de verdad), escuchar a los pacientes y ofrecer soporte nutricional y de ejercicio físico
🍽 🏃♀️
Nuestros datos hablan ... 🙏
🔥 A new prediction tool for malnutrition and sarcopenia in patients with neuroendocrine neoplasms, highlighting the critical role of nutrition and the power of multidisciplinary teamwork across Spain. @GrupoGetne 🤝🥗📊
🧠🍽️ #NUTRIGETNE (GETNE-S2109)
📌 Malnutrition in 62% of patients with GEP-NENs
📌 Sarcopenia in 15%
📌 New predictive score developed by @GrupoGetne to facilitate early nutritional screening in routine practice
💡 Simple, rapid and NET-specific tool.
🔗 https://t.co/NQtzIvWouH
📌Join us on 26 May for an insightful webinar on cortisol-producing #ACC
👉We’ll discuss diagnosis, molecular insights, and emerging therapeutic strategies with leading experts in the field
✍️Speaker: Dr. Terzolo
📅 26 May
🔗 Register here: https://t.co/5UcrKBPAq9
#ACC
Hoy ha arrancado el Preceptorship en Neoplasias Neuroendocrinas organizado por la Dra. Rocío García Carbonero @GCarboneroLab en el Hospital Universitario 12 de Octubre.
Dos días para profundizar en cómo abordar esta patología desde una perspectiva multidisciplinar. Enhorabuena👏🏼
💊📊 Lower-dose everolimus in NETs
✔️ ≤6 mg/day reduced costs by ~42%
→ savings of ~$1137/patient/month
🔹 Drug acquisition = 91% of total expenditure
⚠️ Prior RWE suggests efficacy may be preserved
💡 Dose optimization may improve sustainability of NET care
🔗 https://t.co/wzEVVyRZ6M
Interested in thyroid / endocrine / neuroendocrine neoplasms❓️
Here a practical mini-guide to help navigate #ASCO26 and avoid missing relevant abstracts.
#10añosNET
Si eres paciente o familiar y todavía no te has inscrito en el próximo encuentro presencial en #Burgos todavía estás a tiempo
Juntos avanzamos para mejorar la VIDA de los pacientes 🦓🦓
@netcancerday@GEPAC_@ContraCancerBU@GrupoGetne
🗓️ 15 de mayo
👇👇👇👇
🧠✨ Ya está aquí la Preceptorship en Neoplasias Neuroendocrinas 2026
📍Madrid | 21-22 mayo
🔹 Diagnóstico multidisciplinar
🔹 PRRT y teragnosis
🔹 Casos clínicos y nuevas estrategias terapéuticas
🔹 Expertos nacionales en NEN
🧬💥 Daraxonrasib (RMC-6236) in RASmt PDAC
🔹 Pan-RAS(ON) inhibitor
🔹 ORR: 35% in 2L RAS G12-mutant PDAC
🔹 mPFS: 8.5 mo
🔹 mOS: 13.1 mo
🔹 Responses durable (~8 mo)
🚀 One of the most promising signals yet for targeting RAS-driven PDAC
🔗 https://t.co/pp8ZIa9Wqo
@OncoAlert
🧠 Lifestyle in cancer survivors
⚠️ Advice ≠ action
🔹 Many pts don’t receive counseling
🔹 Even fewer sustain healthy habits
💡 Counseling improves adherence → still underused
🎯 Big opportunity in routine oncology care
🔗 https://t.co/WG7kr5znRi
@OncoAlert@JAMAOnc@myESMO@_SEOM